Fibromyalgia Can Be Assessed in Blood

Fibromyalgia Syndrome (FMS) is an exceptionally common – yet difficult to diagnose – chronic pain condition that is affecting millions around the world. According to the National Fibromyalgia Association, in the United States alone, approximately 10 million people are affected. Globally, 3-6% of the world’s population is estimated to be suffering from it. FMS is a disorder that is especially common among older age groups. By age 80, approximately 8% of adults meet the American College of Rheumatology classification of fibromyalgia.

According to the National Fibromyalgia Association, in the United States alone, approximately 10 million people are affected.

Despite the prevalence of FMS, it’s an elusive syndrome when it comes to its diagnosis. This is due to the myriad of seemingly unrelated symptoms that it’s characterized by. This collection of symptoms predominately includes chronic widespread pain felt throughout the body, as well as fatigue and sleep issues.

Due to the difficulty in diagnosing FMS, it takes on average 5 years before a conclusive diagnosis can be made.

Due to the difficulty in diagnosing FMS, it takes on average 5 years before a conclusive diagnosis can be made. This is time spent suffering, and furthermore, it becomes extremely costly due to numerous healthcare appointments and prescriptions that are required before a diagnosis is finally made.

Our biomarker signature for the disease has allowed us to detect its presence in simple blood samples.

At Paradise Genomics, we’ve developed the most complete set of biomarkers for FMS to date. Our biomarker signature for the disease has allowed us to detect its presence in simple blood samples. We are currently working to collaborate with leading diagnostics companies to develop diagnostic and management tools that can benefit patients suffering from FMS.

The Paradise Genomics gene signature for Fibromyalgia